4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Glenmark Pharmaceuticals Limited (GLENMARK) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 16,946 employees. Its market capitalization is roughly ₹691 billion. In the fiscal year ended 2026-03-31, GLENMARK reported ₹167.1B in revenue and ₹13.6B in net income.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹167.1B | ₹131.5B | ₹116.4B | ₹114.3B | — |
| Gross Profit | ₹116.0B | ₹83.9B | ₹67.6B | ₹68.5B | — |
| Operating Income (EBIT) | ₹40.2B | ₹18.7B | ₹6.3B | ₹10.8B | — |
| Net Income | ₹13.6B | ₹10.5B | (₹15.0B) | ₹3.0B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹39.3B | ₹37.6B | ₹38.9B | ₹60.0B | ₹30.6B | — |
| Gross Profit | ₹26.9B | ₹25.9B | ₹25.9B | ₹47.4B | ₹20.4B | — |
| Operating Income (EBIT) | ₹6.3B | ₹6.1B | ₹7.2B | ₹22.2B | ₹4.5B | — |
| Net Income | ₹4.8B | ₹3.0B | ₹4.0B | ₹6.1B | ₹469M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹1.4B) | (₹704M) | (₹1.2B) | (₹1.4B) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹199.1B | ₹160.5B | ₹143.6B | ₹193.7B | — |
| Total Liabilities | ₹94.0B | ₹72.0B | ₹65.1B | ₹95.3B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GLENMARK viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms